Category Archives: Gene Therapy Clinics

The Global CRISPR Technology Market Size Is Seeing Exponential Growth Due To The Application Of CRISPR Technology In Treating COVID-19 – GlobeNewswire

September 24, 2020 09:00 ET | Source: The Business Research Company

LONDON, Sept. 24, 2020 (GLOBE NEWSWIRE) — (Companies Included: Crispr Therapeutics, Thermo Fisher Scientific, Intellia Therapeutics, Horizon Discovery, and Synthego Corporation)

In another instance, in early May, the US Food and Drug Administration (FDA) granted Sherlock Biosciences an emergency use authorization (EUA) for its COVID-19 diagnostic assay, beating out other companies and academic groups trying to use the powerful gene-editing technology to figure out who is infected with the novel coronavirus. Sherlocks test is the first FDA-authorized use of CRISPR technology for anything. Sherlocks test is a molecular diagnostic, intended to identify people who have acute SARS-CoV-2 infection. It capitalizes on a CRISPR-based technology developed in the lab of Feng Zhang, a scientist at Broad Institute of MIT and Harvard and a cofounder of Sherlock.

The Business Research Companys report titled CRISPR Technology Global Market Report 2020-30: Covid 19 Growth And Change covers the CRISPR market 2020, CRISPR technology market share by company, global CRISPR technology market analysis, global CRISPR technology market size, and CRISPR technology market forecasts. The report also covers the global CRISPR technology market and its segments. The CRISPR technology market share is segmented by product type into Cas9 and gRNA, design tool, plasmid and vector, and other delivery system products. The CRISPR technology market share is segmented by end-user into biopharmaceutical companies, agricultural biotechnology companies, academic research organizations, and contract research organizations (CROs). By application, it is segmented into biomedical, agriculture, diagnostics, and others.

Request A Sample Of The Global CRISPR Technology Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3272&type=smp

The global CRISPR technology market value is expected to grow from $685.5 million in 2019 to $1,654.2 million in 2023 at a compound annual growth rate (CAGR) of 24.6%. The application of CRISPR technology as a diagnostic tool is expected to boost CRISPR technology market growth during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, the US FDA (Food and Drug Administration) announced emergency use authorization of Sherlock BioSciences Inc.s Sherlock CRISPR SARS-CoV-2 kit, which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test.

This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract, and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity, and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will further increase the demand for CRISPR technology products and services and drive the CRISPR market 2020.

Several advancements in CRISPR technology are trending in the market. Advancements in technology will help in reducing errors, limiting unintended effects, improving the accuracy of the tool, widening its applications, developing gene therapies, and more. Scientists, researchers and companies are increasingly developing advanced CRISPR technologies for more precise editing and to get access to difficult to reach areas of human genome. For instance, in March 2020, scientists at University of Toronto developed CHyMErA, a CRISPR-based tool for more versatile genome editing. Similarly, in March 2020, researchers at New York genome center developed a new CRISPR screening technology to target RNA, including RNA of novel viruses like COVID.

In November 2019, researchers at ETH Zurich, Switzerland, swapped CAS9 enzyme for Cas 12a, that allowed the researchers to edit genes in 25 target sites. It is also estimated that hundreds of target sites can be modified using the above method. In October 2019, a team from MIT and Harvard developed new CRISPR genome editing approach called prime editing by combining CRISPR-Cas9 and reverse transcriptase into a single protein. The prime editing has the potential to directly edit human cells with high precision and efficiency.

The CRISPR technology market share consists of sales of CRISPR technology products and services, which is a gene-editing technology that allows researchers to alter DNA sequences and modify gene function. The revenue generated by the market includes the sales of products such as design tools, plasmid & vector, Cas9 & gRNA, and libraries & delivery system products and services that include design & vector construction, screening and cell line engineering. These products and services are used in genome editing/genetic engineering, genetically modifying organisms, agricultural biotechnology and others, which include gRNA database/gene library, CRISPR plasmid, and human stem cell & cell line engineering.

CRISPR Technology Global Market Report 2020-30: Covid 19 Growth And Change is one of a series of new reports from The Business Research Company that provide market overviews, analyze and forecast market size and growth for the whole market, CRISPR technology market segments and geographies, CRISPR technology market trends, CRISPR technology market drivers, CRISPR technology marketrestraints, CRISPR technology market leading competitors revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies. The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modellers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors approaches.

Here Is A List Of Similar Reports From The Business Research Company

Organ-On-Chips Market – By Models (Lung-On-Chip, Heart-On-Chip, Liver-On-Chip, Intestine-On-Chip, Kidney-On-Chip And More), By Applications, And By Region, Opportunities And Strategies Global Forecast To 2023

Healthcare Services Market -By Type (Hospitals And Clinics, Physicians, Nursing Care, Dental Services, Laboratory Services, Ambulance Services And Others), By End User Gender, And By Region, Opportunities And Strategies Global Forecast To 2022

Biobank Market – By Specimens Type (Blood Products, Cell Lines, Nucleic Acids And Human Tissues), And By Region, Opportunities And Strategies Global Forecast To 2023

Gene Editing Global Market Report 2020

Sequencing Market By Type (Next Generation Sequencing, Third Generation Sequencing And Sanger Sequencing), By Products (Consumables, Software, Sequencing Services And Instruments), By Regions And By Trends Global Forecast To 2023

Nucleic Acid Based Gene Therapy Market Global Report 2020

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The Worlds Most Comprehensive Database

The Business Research Companys flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

View original post here:
The Global CRISPR Technology Market Size Is Seeing Exponential Growth Due To The Application Of CRISPR Technology In Treating COVID-19 – GlobeNewswire

Global Gene Therapy Market (by Cell Type, Vector Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19…

The global gene therapy market is expected to reach US$6.42 billion in 2024, witnessing growth at a CAGR of 19.29%, over the period 2020-2024. Growth in the gene therapy market has accrued due to the increasing prevalence of chronic diseases, rising healthcare expenditure, expanding urbanization, growth of gene therapy clinical trials and upsurge in economic growth. The market is anticipated to experience certain trends like rapid adoption of personalized medicine, growing occurrence of genetic disorders, advancements in gene therapy and increasing R&D funding. The growth of the market would be challenged by side effects of gene therapy and ethical and safety concerns and high cost of the treatment.

Get Free Research PDF Of The Report:https://www.researchmoz.us/enquiry.php?type=S&repid=2757028

The global gene therapy market has been segmented on the basis of cell type, vector type, application, end-user and region. Depending on the cell type, the market can be bifurcated into somatic cell gene therapy and germ cell gene therapy. According to the vector type, the global gene therapy market can be categorized into retrovirus & gammaretrovirus, adeno-associated viruses (AAV), lentivirus, adenovirus, modified herpes simplex virus and non-viral plasmid vector. Whereas, on the basis of application, the market can be split into oncological disorders, neurological disorders, infectious diseases, cardiovascular diseases, rare diseases and others. Further, in terms of end-user, the global gene therapy market can broadly be segmented into hospitals, specialty treatment centers and other end-users.

The fastest growing regional market is North America due to the rising incidence of cancer and other target diseases, increasing favorable reimbursement scenario in the region and improvements in healthcare infrastructure. Further, the sudden outbreak of COVID-19 is causing an adverse disruption on the overall economy and society, affecting the rate of gene therapy procedures and clinical trials, which is expected to negatively impact the growth of the global gene therapy market during the forecasted period.

Scope of the report:

Key Target Audience:

Enquiry For Discount Visit:https://www.researchmoz.us/enquiry.php?type=D&repid=2757028

Table of Content

1. Market Overview 1.1 Introduction 1.2 Diseases Treated by Gene Therapy 1.3 Process of Gene Therapy 1.4 Types of Gene Therapy 1.5 Application Areas for Gene Therapy 1.6 Gene Therapy Techniques 1.7 Advantages & Disadvantages of Gene Therapy

2. Impact of COVID-19 2.1 Economic Impact 2.2 Decline in Global GDP 2.3 Decline in Industrial Production 2.4 Impact on Gene Therapy 2.5 Impact on Clinical Trials of Gene Therapy

3. Global Market Analysis 3.1 Global Gene Therapy Market by Value 3.2 Global Gene Therapy Market Forecast by Value 3.3 Global Gene Therapy Market by Cell Type 3.3.1 Global Somatic Cell Gene Therapy Market by Value 3.3.2 Global Somatic Cell Gene Therapy Market Forecast by Value 3.3.3 Global Germ Cell Gene Therapy Market by Value 3.3.4 Global Germ Cell Gene Therapy Market Forecast by Value 3.4 Global Gene Therapy Market by Vector Type 3.4.1 Global Retrovirus & Gammaretrovirus Gene Therapy Market by Value 3.4.2 Global Retrovirus & Gammaretrovirus Gene Therapy Market Forecast by Value 3.4.3 Global Adeno-Associated Viruses Gene Therapy Market by Value 3.4.4 Global Adeno-Associated Viruses Gene Therapy Market Forecast by Value 3.4.5 Global Lentivirus Gene Therapy Market by Value 3.4.6 Global Lentivirus Gene Therapy Market Forecast by Value 3.4.7 Global Adenovirus Gene Therapy Market by Value 3.4.8 Global Adenovirus Gene Therapy Market Forecast by Value 3.4.9 Global Modified Herpes Simplex Virus Gene Therapy Market by Value 3.4.10 Global Modified Herpes Simplex Virus Gene Therapy Market Forecast by Value 3.4.11 Global Non-Viral Plasmid Vector Gene Therapy Market by Value 3.4.12 Global Non-Viral Plasmid Vector Gene Therapy Market Forecast by Value 3.5 Global Gene Therapy Market by Application 3.5.1 Global Oncological Disorders Gene Therapy Market by Value 3.5.2 Global Oncological Disorders Gene Therapy Market Forecast by Value 3.5.3 Global Neurological Disorders Gene Therapy Market by Value 3.5.4 Global Neurological Disorders Gene Therapy Market Forecast by Value 3.5.5 Global Infectious Disease Gene Therapy Market by Value 3.5.6 Global Infectious Disease Gene Therapy Market Forecast by Value 3.5.7 Global Cardiovascular Diseases Gene Therapy Market by Value 3.5.8 Global Cardiovascular Diseases Gene Therapy Market Forecast by Value 3.5.9 Global Rare Diseases Gene Therapy Market by Value 3.5.10 Global Rare Diseases Gene Therapy Market Forecast by Value 3.6 Global Gene Therapy Market by End-User 3.6.1 Global Hospitals & Clinics Gene Therapy Market by Value 3.6.2 Global Hospitals & Clinics Gene Therapy Market Forecast by Value 3.6.3 Global Specialty Treatment Centers Gene Therapy Market by Value 3.6.4 Global Specialty Treatment Centers Gene Therapy Market Forecast by Value 3.7 Global Gene Therapy Market by Region

4. Regional Market Analysis 4.1 North America 4.1.1 North America Gene Therapy Market by Value 4.1.2 North America Gene Therapy Market Forecast by Value 4.2 Europe 4.2.1 Europe Gene Therapy Market by Value 4.2.2 Europe Gene Therapy Market Forecast by Value 4.2.3 Europe Gene Therapy Market by Indication 4.2.4 Europe Large B-Cell Lymphoma Gene Therapy Market by Value 4.2.5 Europe Large B-Cell Lymphoma Gene Therapy Market Forecast by Value 4.2.6 Europe Inherited Retinal Disease Gene Therapy Market by Value 4.2.7 Europe Inherited Retinal Disease Gene Therapy Market Forecast by Value 4.2.8 Europe ADA-SCID Gene Therapy Market by Value 4.2.9 Europe ADA-SCID Gene Therapy Market Forecast by Value 4.2.10 Europe Acute Lymphoblastic Leukemia Gene Therapy Market by Value 4.2.11 Europe Acute Lymphoblastic Leukemia Gene Therapy Market Forecast by Value 4.3 Asia Pacific 4.3.1 Asia Pacific Gene Therapy Market by Value 4.3.2 Asia Pacific Gene Therapy Market Forecast by Value .4 RoW 4.4.1 RoW Gene Therapy Market by Value 4.4.2 RoW Gene Therapy Market Forecast by Value

Continue

Inquire More About This Report:https://www.researchmoz.us/enquiry.php?type=E&repid=2757028

For More Information Kindly Contact: ResearchMoz Mr. Rohit Bhisey, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Email: [emailprotected] Follow me on : http://marketresearchlatestreports.blogspot.com/

More here:
Global Gene Therapy Market (by Cell Type, Vector Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19…

Redwood Coast PACE Celebrates Its Sixth Anniversary and National PACE Month – Redheaded Blackbelt

Redwood Coast PACE, a program of the Humboldt Senior Resource Center, is celebrating both its sixth anniversary and National PACE Month in September. We are taking this opportunity to raise awareness and celebrate the difference that Redwood Coast PACE a Program of All-inclusive Care for the Elderly makes in the lives of our participants, their families, and our community.

The PACE model of care has allowed Redwood Coast PACE to bring to Humboldt County a model of care that provides older adults with long-term care needs and their families the most freedom to live their lives in the community, said Barbara LaHaie, program director. Redwood Coast PACE also holds the distinction of being the first rural PACE program in California, and a model for other rural programs in the state and country.

In order to enroll in Redwood Coast PACE, a person must be age 55 or over, live in the program service area that stretches from north of Trinidad south to Scotia, need a nursing home level of care, and be able to live safely in the community with the support of PACE. The program provides not only comprehensive primary and specialty medical care, but also dental and vision care, hospitalization and emergency services, day center services, physical and other therapy, all transportation to the center and medical appointments, care coordination, in-home care, all medications, durable medical equipment, and more.

Redwood Coast PACE now serves 209 participants, and recently opened a second Center and Clinic in Fortuna on the Gene Lucas Community Center campus, located at 3200 Newburg Road. The Fortuna Center primarily serves participants living in the Eel River Valley, who now have services closer to home, while the Eureka Center serves participants from the northern Humboldt PACE service area.

Across the nation, PACE organizations care for 95 percent of their enrollees in the community rather than in a nursing home. PACE is a quickly growing care model that has been in operation for more than 30 years. A total of 134 organizations operate 264 PACE centers in 31 states. Currently, more than 51,000 individuals are enrolled in the program. Caring for older individuals with multiple health care needs has been particularly challenging during this pandemic, said Melissa Hooven, Humboldt Senior Resource Center CEO. To keep participants and staff as safe as possible, the PACE model of care has been adapted from bringing participants into a PACE center several times a week to providing services in the home. The resilience of the model in the face of this pandemic has been extremely effective.

During the pandemic, Redwood Coast PACE staff have utilized telemedicine to communicate with and care for participants, from telephone calls to specialized technology via tablets in the home. Our staff has worked to find new ways to engage participants who often miss their friends at the PACE Center. The clinics at the PACE Centers in both Eureka and Fortuna have remained open to serve participants by appointment.

Referrals are now being accepted for both the Eureka and Fortuna PACE centers. For more information, call 70-443-9747 or visit www.humsenior.org.

###

About the Humboldt Senior Resource Center

The Humboldt Senior Resource Center (HSRC) is committed to ensuring the best possible quality of life for seniors, their caregivers and their families. We support and encourage independence, dignity and well-being for all older adults in our community through a comprehensive array of health, nutrition, and educational services as well as opportunities for friendship and social interaction. Our programs include Redwood Coast PACE, a Program of All-inclusive Care for the Elderly that provides comprehensive medical care and support services; Adult Day Health & Alzheimers Services, a state-licensed therapeutic day program; senior dining centers in Arcata, Eureka and Fortuna; home-delivered meals; recreational activities; the Multipurpose Senior Services Program (MSSP), which provides care management services for frail seniors; and the monthly Senior News newspaper. We have numerous philanthropic and volunteer opportunities. For more information or to make a donation, call 707.443.9747 or email [emailprotected]

This e-mail message, including any attachments may contain confidential and privileged information. Any unauthorized use, disclosure, or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

Originally posted here:
Redwood Coast PACE Celebrates Its Sixth Anniversary and National PACE Month – Redheaded Blackbelt

Cancer Therapy Market 2020 Size and Share by Growth Opportunities, Segmentation, Regional Insights, Key Trends, Demand and Outlook by 2024 – Verdant…

Several big pharmaceutical companies, such as Pfizer and Eli lily, have also started these programs to help uninsured patients who are suffering from chronic diseases. Thus, a large number of uninsured patients, suffering from cancer, can also undergo cancer therapies, which is likely to augment the growth of the market.

Scope of the Report:

As per the , cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells. These therapies include surgery, radiation therapy, chemotherapy, immunotherapy, etc.

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999546

Key Market Trends:

The Target Therapy Segment is Expected to show the Fastest Growth in the Forecast Period

The target therapy segment is expected to show the highest CAGR of 9.68% during the forecast period. The target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells.

The breast cancer segment is belived to account for the largest market size over the forecast period. This is majorly attrobuted to the higher and continuously increaisng prevalence of breast cancer acoss the world. As per estimates provided by the Breast Cancer Organization in 2018, it is estimated that over 2,66,120 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, along with 63,960 new cases of non-invasive (in situ) breast cancer.

North America Currently Dominates the Cancer Therapy Market and is Expected to Continue in the Forecast Period

North America currently dominates the market for cancer therapy and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of cancer therapy. The United States holds majority of the market in the North American region, due to the rising prevalence of cancer in the country. According to the National Cancer Institute (NCI), in 2016, 1.6 million people suffered from cancer, and around 0.5 million people died from cancer. This figure indicates that the prevalence of cancer is rapidly increasing in the United States.

Cancer Therapy Market Report contents include:

Purchase this Report (Price 4500 USD for single user license) https://www.industryresearch.co/purchase/13999546

Detailed TOC of Cancer Therapy Market Report 2020-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increasing Patient Assistance Programs (PAPs) 4.2.2 Growing Government Initiatives for Cancer Awareness 4.2.3 Rising Prevalence of Cancer Worldwide 4.2.4 Strong R&D Initiatives from Key Players 4.3 Market Restraints 4.3.1 Fluctuation in Reimbursement Policies 4.3.2 High Cost of Cancer Therapies 4.4 Porters Five Force Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Treatment Type 5.1.1 Chemotherapy 5.1.2 Targeted Therapy 5.1.3 Immunotherapy 5.1.4 Hormonal Therapy 5.1.5 Other Treatment Types 5.2 By Cancer Type 5.2.1 Blood Cancer 5.2.2 Breast Cancer 5.2.3 Prostate Cancer 5.2.4 Gastrointestinal Cancer 5.2.5 Gynecologic Cancer 5.2.6 Respiratory/Lung Cancer 5.2.7 Other Cancer Types 5.3 By End User 5.3.1 Hospitals 5.3.2 Spcialty Clinics 5.3.3 Cancer and Radiation Therapy Centers 5.4 Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 South Korea 5.4.3.5 Australia 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle East & Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East & Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Amgen Inc. 6.1.2 AstraZeneca PLC 6.1.3 Bayer AG 6.1.4 Johnson and Johnson 6.1.5 Merck & Co. Inc. 6.1.6 F. Hoffmann-La Roche AG 6.1.7 Eli Lilly and Company 6.1.8 Novartis AG 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

About Industry Research:

Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Ophthalmic Ultrasound Systems Market Size by Impressive Growth Rate 2020 Business Size, Global Share, Industry Overview by Future Plans, Top Key Players Forecast to 2026 | Report by Industry Research.co

Bouillon Cubes Market Size by Impressive Growth Rate 2020 Business Size, Global Share, Industry Overview by Future Plans, Top Key Players Forecast to 2026 | Report by Industry Research.co

Ultra-Thin Glass Market Growth Analysis by Future Trends 2020 Industry Size by Top Players, Development Plans, Business Share, Revenue and Opportunities till 2026

Foldable Display Market Size by Future Scope 2020 | Global Industry Revenue, Share, Future Demand Status, Growth Segmentations Analysis by Regions Forecast to 2026

Intravenous (IV) Solution Market Growth Analysis by Future Trends 2020 Industry Size by Top Players, Development Plans, Business Share, Revenue and Opportunities till 2026

Brine Concentration Market Size Analysis 2020 Global Industry Scope, Key Players, Top Regions, Current Industry Trend with Growth Rate, CAGR Status Forecast to 2026 | Report by Industry Research.co

Artificial Joint Replacement Market Size Report 2020 Market Dynamics and Developments, Industry Research Report by Top Manufactures, Types, Applications Forecast to 2026

Follow this link:
Cancer Therapy Market 2020 Size and Share by Growth Opportunities, Segmentation, Regional Insights, Key Trends, Demand and Outlook by 2024 – Verdant…

Impact Of Covid-19 on Alpha Thalassemia Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 – Crypto Daily

Global Alpha Thalassemia Market 2025 Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2025 is Provided to Determine the Market Potential.

Alpha Thalassemia Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025 The study of Alpha Thalassemia market is a compilation of the market of Alpha Thalassemia broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Alpha Thalassemia industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Request a sample of Alpha Thalassemia Market report @ https://hongchunresearch.com/request-a-sample/61906

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Alpha Thalassemia industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

The following manufacturers are covered: Bluebird Bio Novartis Kiadis Pharma Acceleron Pharma

Access this report Alpha Thalassemia Market @ https://hongchunresearch.com/report/worldwide-alpha-thalassemia-market-2019-61906

Segment by Regions North America Europe China Japan

Segment by Type Iron Chelating Drugs Gene Therapy

Segment by Application Hospitals Private clinics Other

For a global outreach, the Alpha Thalassemia study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses: Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitions Revenue, cost price, capacity & utilizations, import/export rates and market share Forecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Alpha Thalassemia Market @ https://hongchunresearch.com/check-discount/61906

Major Point of TOC:

Chapter One: Alpha Thalassemia Market Overview

Chapter Two: Global Alpha Thalassemia Market Competition by Manufacturers

Chapter Three: Global Alpha Thalassemia Production Market Share by Regions

Chapter Four: Global Alpha Thalassemia Consumption by Regions

Chapter Five: Global Alpha Thalassemia Production, Revenue, Price Trend by Type

Chapter Six: Global Alpha Thalassemia Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Alpha Thalassemia Business

Chapter Eight: Alpha Thalassemia Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Alpha Thalassemia Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Author List 13.4 Disclaimer

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer Gray Manager Global Sales + 852 8170 0792 [emailprotected]

Read more:
Impact Of Covid-19 on Alpha Thalassemia Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 – Crypto Daily

AstraZeneca : Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian…

AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on a biomarker subgroup analysis of the PAOLA-1 Phase III trial, which was published in The New England Journal of Medicine.

The trial showed that Lynparza in combination with bevacizumab maintenance treatment reduced the risk of disease progression or death by 67% (based on a hazard ratio of 0.33; 95% confidence interval 0.25-0.45). The addition of Lynparza improved progression-free survival (PFS) to a median of 37.2 months versus 17.7 months with bevacizumab alone in patients with HRD-positive advanced ovarian cancer.

For patients with advanced ovarian cancer, the primary aim of 1st-line treatment is to delay disease progression for as long as possible with the intent to achieve long-term remission.1-3

Ovarian cancer is the fifth most common cause of cancer death in Europe and the five-year survival rate is approximately 45%, due in part because women are often diagnosed with advanced disease (Stage III or IV).4,5

Jos Baselga, Executive Vice President, Oncology R&D, said: ‘Half of all newly diagnosed patients with advanced ovarian cancer have HRD-positive tumours. Lynparza together with bevacizumab has demonstrated a median progression-free survival benefit of more than three years, offering new hope for women in this setting. This recommendation is a vital step toward addressing a significant unmet need and could bring a new treatment option that delays relapse in this devastating disease.’

Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, MSD Research Laboratories, said: ‘HRD is an important biomarker of advanced ovarian cancer that can inform how physicians in the EU treat this aggressive type of cancer. This recommendation and the results from the PAOLA-1 trial underscore the importance of HRD testing at diagnosis to determine the best course of treatment for women with advanced ovarian cancer.’

The CHMP recommendation is for Lynparza in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of 1st-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with HRD positive status defined by either a breast cancer susceptibility gene 1/2 (BRCA1/2) mutation and/or genomic instability.

Further results from the PAOLA-1 trial recently presented during the 2020 European Society for Medical Oncology virtual congress showed that Lynparza in combination with bevacizumab maintenance treatment demonstrated a statistically significant improvement in the time to second disease progression (PFS2) versus bevacizumab alone in patients with HRD-positive advanced ovarian cancer, a key secondary endpoint. The results showed Lynparza with bevacizumab provided benefit beyond first disease progression, improving PFS2 to a median of 50.3 months versus 35.3 months with bevacizumab alone.

Lynparza in combination with bevacizumab is approved in the US and several other countries as a 1st-line maintenance treatment for patients with HRD-positive advanced ovarian cancer and is currently under regulatory review in other countries around the world.

Ovarian cancer

In 2018, there were nearly 68,000 new cases of ovarian cancer diagnosed in Europe and around 45,000 deaths.4 Approximately 50% of ovarian cancers are HRD-positive including BRCA1/2 mutation.6,7 Approximately 22% of ovarian cancers have a BRCA1/2 mutation.6-8

Homologous recombination deficiency

HRD, which defines a subgroup of ovarian cancer, encompasses a wide range of genetic abnormalities, including BRCA mutations and beyond. As with BRCA gene mutations, HRD interferes with normal cell DNA repair mechanisms and confers sensitivity to PARP inhibitors including Lynparza.9

PAOLA-1

PAOLA-1 is a double-blind Phase III trial testing the efficacy and safety ofLynparzaadded to standard-of-care bevacizumab versus bevacizumab alone, as a 1st-line maintenance treatment for newly diagnosed advanced FIGO Stage III-IV high-grade serous or endometroid ovarian, fallopian tube, or peritoneal cancer patients who had a complete or partial response to 1st-line treatment with platinum-based chemotherapy and bevacizumab. AstraZeneca and MSD announced in August 2019 that the trial met its primary endpoint of PFS in the overall trial population.

Lynparza

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in homologous recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2. Inhibition of PARP with Lynparza leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death. Lynparza is being tested in a range of PARP-dependent tumour types with defects and dependencies in the DDR pathway.

Lynparza is currently approved in a number of countries, including those in the EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer. It is approved in the US, the EU, Japan, China, and several other countries as 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer following response to platinum-based chemotherapy. It is also approved in the US as a 1st-line maintenance treatment with bevacizumab for patients with HRD-positive advanced ovarian cancer (BRCAm and/or genomic instability). Lynparza is approved in the US, Japan, and a number of other countries for germline BRCA-mutated, HER2-negative, metastatic breast cancer, previously treated with chemotherapy; in the EU, this includes locally advanced breast cancer. It is also approved in the US and several other countries for the treatment of germline BRCAm metastatic pancreatic cancer. Lynparza is approved in the US for HRR gene-mutated mCRPC (BRCAm and other HRR gene mutations). Regulatory reviews are underway in several countries for ovarian, breast, pancreatic and prostate cancers.

Lynparza, which is being jointly developed and commercialised by AstraZeneca and MSD, has been used to treat over 30,000 patients worldwide. Lynparza has the broadest and most advanced clinical trial development programme of any PARP inhibitor, and AstraZeneca and MSD are working together to understand how it may affect multiple PARP-dependent tumours as a monotherapy and in combination across multiple cancer types. Lynparza is the foundation of AstraZeneca’s industry-leading portfolio of potential new medicines targeting DDR mechanisms in cancer cells.

The AstraZeneca and MSD strategic oncology collaboration

In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US, known as MSD outside the US and Canada, announced a global strategic oncology collaboration to co-develop and co-commercialise Lynparza, the world’s first PARP inhibitor, and Koselugo (selumetinib), a mitogen-activated protein kinase (MEK) inhibitor, for multiple cancer types. Working together, the companies will develop Lynparza and Koselugo in combination with other potential new medicines and as monotherapies. Independently, the companies will develop Lynparza and Koselugo in combination with their respective PD-L1 and PD-1 medicines.

AstraZeneca in oncology

AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio ofnew medicines that has the potential to transform patients’ lives and the Company’s future. With seven new medicines launched between 2014 and 2020, and a broad pipelineof small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and, one day, eliminate cancer as a cause of death.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

References

1. Raja et al. (2012). Optimal first-line treatment in ovarian cancer. Annals on Oncology. 23 Suppl 10, x118-127.

2. NHS Choices, Ovarian Cancer Available at: https://www.nhs.uk/conditions/ovarian-cancer/treatment/ [Accessed September 2020].

3. Ledermann et al. (2013). Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24, pp.vi24-vi32.

4. The World Health Organization. IARC. Globocan. (2018). Available at: http://gco.iarc.fr/ [Accessed September 2020].

5. EuroHealth. (2018). Ovarian Cancer: The Silent Killer. Available at: https://eurohealth.ie/policy-brief-women-and-ovarian-cancer-in-the-eu-2018/ [Accessed September 2020].

6. Moschetta et al. (2016). BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Annals of Oncology, 27(8), pp.1449-1455.

7. Bonadio et al. (2018). Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics, 73(Suppl 1): e450s.

8. Pothuri. (2013). BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Annals of Oncology, 24.

9. Moore, K. (2018). Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 379(26), pp.2495-2505.

See more here:
AstraZeneca : Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian…

Impact of Covid-19 | Retinitis Pigmentosa (Retinitis) Market Report Examines Business Opportunity and Worldwide Scope by Forecast 2020 to 2025 – Galus…

A new report titled, Global Retinitis Pigmentosa (Retinitis) Market Professional Report 2020-2025 has been added by Garner Insights in its database of research reports. The scope of the report includes a comprehensive study of global, regional, and local markets for different segments of the market.

The study provides complete details about the usage and adoption of Retinitis Pigmentosa (Retinitis) in various industrial applications and geographies. This helps the key stakeholders in knowing about the major development trends, growth strategies, investments, vendor activities, and government initiatives. Moreover, the report specifies the major drivers, restraints, challenges, and lucrative opportunities that are going to impact the growth of the market.

Request Sample Report of Global Retinitis Pigmentosa (Retinitis) Market @https://garnerinsights.com/2015-2025-Global-Retinitis-Pigmentosa-Retinitis-Market-Research-by-Type-End-Use-and-Region-COVID-19-Version#request-sample

Key Players: Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences, Dompe Farmaceutici SpA, Dormant Projects, GenSight Biologics SA, Grupo Ferrer Internacional SA, ID Pharma, InFlectis BioScience, Ionis Pharmaceuticals, Mimetogen Pharmaceuticals, Ms Science Corp, Nanovector srl, Novartis AG, Novelion Therapeutics, ProQR Therapeutics, ReNeuron Group Plc, SanBio, Shire (Takeda Pharmaceutical), Spark Therapeutics

Types:

General Treatment Traditional Chinese Medicine Gene Therapy The Surgical Treatment Others

Application:

Hospitals Eye Clinics Others

The report calculates the size of the Global Retinitis Pigmentosa (Retinitis) Market using a bottom-up approach, where data from various end-user industries and its applications across product types were recorded. This data was sourced from the industry experts and company representatives and externally validated through studying historical data of these product types and applications for getting an appropriate size of the Retinitis Pigmentosa (Retinitis) Market. The report conducted secondary research from sources such as company website, news articles, financial reports, press releases, investor presentations, and company annual reports.

Grab Your Report at an Impressive Discount! Please click Here@ https://garnerinsights.com/2015-2025-Global-Retinitis-Pigmentosa-Retinitis-Market-Research-by-Type-End-Use-and-Region-COVID-19-Version#discount

This report forecasts revenue growth at the global, regional, and local levels and provides an analysis of the most recent industry trends from 2020 to 2025 in each of the segments and sub-segments. In addition, the report highlights the impact of COVID-19 on the Global Retinitis Pigmentosa (Retinitis) Market. Some of the major geographies included in the market are given below:

North America (U.S., Canada) Europe (U.K., Germany, France, Italy) Asia Pacific (China, India, Japan, Singapore, Malaysia) Latin America (Brazil, Mexico) Middle East & Africa

The key objectives of the Study: To analyze and forecast the size of the Global Retinitis Pigmentosa (Retinitis) Market in terms of value and volume. To study and provide the market segmentation in detail based on the geography by segmenting the Global Retinitis Pigmentosa (Retinitis) Market into five regions, namely, North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. To study, identify, and forecast the Global Retinitis Pigmentosa (Retinitis) Market by carrying out SWOT analysis, Porters Five Forces analysis, and Pester analysis. To study the competitive developments such as technological developments, services, and regulative initiatives within the Global Retinitis Pigmentosa (Retinitis) Market. To highlight the impact analysis of the factors affecting the market dynamics such as drivers, restraints, opportunities, and challenges. To strategically profile the leading industry players and thoroughly analyze their overall shares in the market, along with detailing the competitive advantage.

Request customized copy of report @https://garnerinsights.com/2015-2025-Global-Retinitis-Pigmentosa-Retinitis-Market-Research-by-Type-End-Use-and-Region-COVID-19-Version

Continue reading here:
Impact of Covid-19 | Retinitis Pigmentosa (Retinitis) Market Report Examines Business Opportunity and Worldwide Scope by Forecast 2020 to 2025 – Galus…

Hemophilia Treatment Market: Trends, Applications, Industry Competitive Analysis, Growth,Forecast: 2019 to 2029 – The News Brok

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hemophilia Treatment market.

Trusted Business Insights presents an updated and Latest Study on Hemophilia Treatment Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hemophilia Treatment market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hemophilia Treatment Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Hemophilia Treatment Market Industry / Sector Trends

Hemophilia Treatment Market size was valued USD 10.5 billion in 2018 and is expected to witness 5.0% CAGR from 2019 to 2025.

U.S. hemophilia treatment market, by disease, 2018 & 2025 (USD Million)

Growing prevalence of hemophilia across the globe will be one of the major market augmenting factors over the forthcoming years. As per the recent statistics published by Centers for Disease Control and Prevention (CDC), hemophilia A affects around 1 in 5,000 live male births in the U.S. Majority of the people with hemophilia are diagnosed at a young age. According to the CDC data, average age of hemophilia diagnosis in the U.S. is 36 months for mild hemophilia, 8 months for moderate hemophilia and 1 month for severe hemophilia. Hence, rise in number of people suffering from hemophilia will enhance the hemophilia treatment market growth in the near future.

Rise in several government initiatives will augment the industry growth over the projection period. Organization including the World Hemophilia Organization along with governments of several countries carry out awareness and diagnosis programs. Government efforts to enhance public health and treat underprivileged people will result in boosting the hemophilia treatment market growth in the near future.

However, high cost of hemophilia medications will be one the major growth impeding factors. High investment, R&D, manufacturing and marketing of drugs by manufacturers is the reason for high cost of the products. High cost of products are unaffordable for the middle and lower income class families, thus resulting in restraining the business growth.

Market Segmentation, Outlook & Regional Insights: Hemophilia Treatment Market

Hemophilia Treatment Market, By Disease

Germany hemophilia treatment market share, by disease, 2018

Hemophilia A treatment market was valued at USD 6,743.7 million in the year 2018. Hemophilia A is a common blood disorder and the prevalence rate is high in developing and underdeveloped regions. As per the recent statistics, around 19,000 people in India suffer from hemophilia and only 15% of the patients are registered. Increase in number of people suffering from hemophilia A and rise in awareness among the people regarding the treatment and medications of hemophilia will result in rise in demand and adoption rate of hemophilia drugs, fueling the business growth.

Hemophilia B treatment market is estimated to grow at 4.0% over the estimation period. As per a recent research article, the prevalence of hemophilia B is quite rare as compared to hemophilia A and the incidence of hemophilia B is around 1 in 30,000 in the U.S. Recent technological advancements has led to growing medications for hemophilia B treatment, hence resulting in boosting the segmental growth.

Hemophilia Treatment Market, By Product

Recombinant factor concentrates market was valued at USD 6,626.9 million in the year 2018. Rise in production of recombinant factor concentrates has provided growth opportunity to treat hemophilia and overcome limited availability of plasma-derived concentrates. Also, increased safety of replacement therapy with the help of recombinant factor concentrates has dramatically enhanced the quality of patient life. Increase in preference of recombinant factor concentrates in treatment of hemophilia will ultimately lead to augmenting the business growth over the forecast period.

Extended half-life products market is estimated to witness a robust growth of 5.3% over the forecast period. Recent research and development has led to the production of new factor concentrates that are efficient and need less frequent injections. The reason for fewer injections are due to the increased half-life of the product. Hence, recent technological advancements and new product launches will lead to increase in demand and adoption rate of extended half-life products, thereby fueling the business growth.

Hemophilia Treatment Market, By Patient

Hemophilia treatment in adults was valued at USD 6,778.1 million in the year 2018. As per a recent research article, around 65% of the people suffering from hemophilia are adults. In some of the adults mild hemophilia is diagnosed in the later stages of life. As the age of patients increases, the need for hemophilia care also increases. There are various possibilities of developing moderate to severe hemophilia in adults. Hence, growing age results in rise in chances of developing hemophilia in adults, thereby boosting the demand for hemophilia treatment in the near future.

Hemophilia treatment in pediatrics is projected to grow at 5.2% over the estimation period. Hemophilia is inherited diseases that are passed to children from gene located on X-chromosome. In approximately one third of children, no family history of hemophilia is found, and the disease occurs due to gene mutation. Children with hemophilia gene bruise easily, bleed more with surgeries and have frequent nose bleedings. According to the National Center for Biotechnology Information, severe form of factor deficiencies including hepatitis A and hepatitis B were diagnosed in the neonates with 52% and 68% of cases respectively. Hence, increase in prevalence of hemophilia in children will augment the hemophilia treatment market growth in the near future.

Hemophilia Treatment Market, By Treatment

Prophylaxis treatment market was valued at USD 7,219.9 million in the year 2018. Long-term prophylaxis treatment is considered as standard of care to prevent chronic arthropathy and joint bleeding in patients with severe hemophilia. As per a recent research, it was observed that the prophylaxis treatment for hemophilia was quite effective and slowed the progression of joint damage. Majority of patients and healthcare providers opt for prophylaxis treatment owing to its efficiency and better end results. Hence, increase in preference of prophylaxis treatment will further augment the business growth in the near future.

On demand treatment market is estimated to grow at 5.2% over the forthcoming years. People suffering from mild to moderate hemophilia are treated with on demand treatment to prevent bleeding. Children with severe hemophilia initially receive prophylactic therapy to prevent bleeding; however, after reaching adulthood, they switch to on-demand treatment for several reasons, such as strict work schedules, inconvenience of visiting doctors or going to a clinic several times a week, along with high expenditure related to continuous prophylactic therapy. Hence, the aforementioned reasons will be responsible for the market growth of on demand treatment segment.

Hemophilia Treatment Market, By Therapy

Factor replacement therapy market was valued at USD 9,574.2 million in the year 2018. As per the Medical and Scientific Advisory Council (MASAC) of National Hemophilia Foundation (NHF), the use of recombinant factor concentrates in children is quite effective as the recombinant factor does not contain actual human blood and cannot transmit harmful viruses including hepatitis. Hence, the use of factor replacement therapy is quite common due to direct infusion of clotting factors, resulting in boosting the segmental growth.

Non-factor replacement therapy is projected to show rapid growth of 38.3% over the estimation period. One of the challenging problems in the treatment of hemophilia is the development of alloantibodies against the infused factor concentrates. Development of inhibitors render the factor replacement therapy ineffective, leading to high risk of morbidity and mortality in patients. Also, there is growing interest in non-factor replacement therapy agents that act by inhibiting anticoagulant pathways or enhancing coagulation. Hence, introduction of new therapeutic agents in hemophilia treatment will enhance the business growth.

Hemophilia Treatment Market, By Drug Class

Coagulation factors market was valued at USD 9,948.3 million in the year 2018. Hemophilia is considered as hereditary blood disease with coagulation time. The use of coagulation factors is quite common and is used mostly in the replacement therapy. Absence or improper functioning of several clotting factors in the blood such as factors VIII, XI, etc. result in causing hemophilia. Hence, use of several clotting factors to replace the absent blood clotting factors will lead to boosting the hemophilia treatment market growth.

Vasopressin drug class market is estimated to grow at 6.0% in the near future. Patients suffering from mild hemophilia use vasopressin drugs for joint and muscle bleeds, bleeding in mucous membranes of nose and mouth and pre and post-surgery. Vasopressin drugs comes in injectable and nasal spray form and is comparatively easy to use. Hence, the aforementioned factors will be responsible for the market growth of vasopressin drug class.

Hemophilia Treatment Market, By Route of Administration

Injectable route of administration for hemophilia treatment was valued at USD 9,629.3 million in the year 2018. Majority of the drugs and factor concentrate products are intravenously given to patients for better and quick results. Intravenous route of administration helps the medications to directly interact with the blood. Hence, majority of healthcare providers opt for injectable or intravenous route of drug administration to treat hemophilia for better and quick results, hence boosting the market growth.

Nasal spray or intra nasal route of administration will grow at 6.0% over the forecast period. Drugs including vasopressin are required to be taken by patients for joint and muscle bleeds, and bleeding in mucous membranes of nose and mouth. Several advantages offered by nasal spray such as ease of use and user convenience will result in growing demand, thereby fueling the business growth.

Hemophilia Treatment Market, By End-use

Hemophilia treatment centers as end-use was valued at USD 4,134.6 million in the year 2018. A substantial proportion of hemophilia treatment is carried out in such centers. During the forecast period, the hemophilia treatment center end-use market segment will continue to lead, owing to rising number of special care provided and peoples increased preference for these centers over other healthcare settings.

Clinics as end-use is estimated to grow at 5.3% in the near future. Clinics provide fast-track treatment and infusion of factor concentrates to patients. Also, immediate and short-time treatment provided during the daytime to people with busy and hectic work schedule will enhance business growth in the near future.

Hemophilia treatment Market, By Region

Europe hemophilia treatment market, by country, 2025 (USD Million)

U.S. dominated the North America hemophilia treatment market and was valued at USD 3,539.3 million in the year 2018. As per the Hemophilia Federation of America, hemophilia A affects around 1 in 5,000 people in the U.S. and approximately 400 new-borns are diagnosed with hemophilia every year. Also, presence of favorable reimbursement and insurance in the country will result in growing demand and adoption rate of hemophilia medications, expanding the hemophilia treatment market growth in the country.

India hemophilia treatment market is projected to grow at 9.2% over the estimation period. Various government initiatives has helped in building necessary infrastructure, empower healthcare providers and patients to self-administer treatment at home, hence helping patients achieve a better quality of life. Recent technological advancements, rise in awareness among people, new product launches and government initiatives will augment the business growth over the forecast period.

Key Players, Recent Developments & Sector Viewpoints: Hemophilia Treatment Market

Major industry players involved in the hemophilia treatment market include Swedish Orphan Biovitrum AB, Sanofi SA, Pfizer, Novo Nordisk, Genentech, CSL Behring, Biogen, among other market players. These players have implemented several strategic initiatives such as collaborations, merger and acquisitions, new product launches and partnerships that have enhanced their financial stability, helped them evolve as major industrial players and gain strong market position.

Hemophilia Treatment Industry Viewpoint

Hemophilia has been an extremely old and critical disease that the global population has been facing. People in ancient times have written and articulated about bleeding problems. Some of the bleeding problems identified have been different as compared to others. But little they knew about blood clots and the disease caused by their deficiency. Until before World War II, doctors learned about hemophilia A and its cause due to deficiency of factor VIII. Several other blood factors were recognized later on and Roman numeral names were given to avoid confusion. Hemophilia research has come a long way with scientists discovering human blood in different groups, hence helping blood transfusions to be more successful. In 1960s, Dr. Judith Pool discovered a procedure to freeze and thaw plasma to get a layer of factor-rich plasma called as cryoprecipitate. Use of cryoprecipitate was the best way of stopping hemophilia bleeding. Later on, the greatest breakthrough that came in hemophilia treatment was the development and introduction of factor concentrates. These clotting factors can be freeze-dried to a powder that can be easily stored and consumed. With the help of these factor concentrates, people suffering from hemophilia can be treated quickly with maximum efficiency. Also, factor concentrates have helped people treat their bleedings at home or at work, resulting in people to lead normal lives. Also, development and introduction of new medications and technologies such as non-factor replacement therapy, extended half-life products, gene therapy, etc. will augment the growth of hemophilia treatment market growth in the near future.

Key Insights Covered: Exhaustive Hemophilia Treatment Market 1. Market size (sales, revenue and growth rate) of Hemophilia Treatment industry. 2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Hemophilia Treatment industry. 3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Hemophilia Treatment industry. 4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Hemophilia Treatment industry.

Research Methodology: Hemophilia Treatment Market

Looking for more? Check out our repository for all available reports on Hemophilia Treatment in related sectors.

Quick Read Table of Contents of this Report @ Hemophilia Treatment Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

See the article here:
Hemophilia Treatment Market: Trends, Applications, Industry Competitive Analysis, Growth,Forecast: 2019 to 2029 – The News Brok

Menkes SyndromeIndustry 2020 With Covid-19 Impact on Market Research by Size, Top Leading Countries, Companies, Consumption, Drivers, Trends, Forces…

Data Bridge Market Research recently introducedGlobal Menkes Syndrome Market Size, Industry Share, Growth, Industry Trends and Forecast To 2020study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2020.Menkes Syndrome Industry 2020 GlobalMarket Research report 2020 covers a detailed study of the Menkes Syndrome Market size, growth, and share, trends, consumption, segments, application and Forecast 2020. The study objective of this report is to analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. The market type, organization size, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa are kept into focus while creating this global Menkes Syndrome market report. The growth of the Menkes Syndrome market was mainly driven by the increasing R&D spending across the world, howeverlatest COVID scenarioand economic slowdown have changed complete market dynamics.

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-menkes-syndrome-market

KNOW YOUR OPTIONS IN THE FIGHT AGAINST COVID-19

The COVID-19 Pandemic has created bottlenecks across industry pipelines, sales funnels, and supply chain activities. This has created unprecedented budget pressure on company spending for industry leaders. This has increased requirement for opportunity analysis, price trend knowledge and competitive outcomes. Use the DBMR team to create new sales channels and capture new markets previously unknown. DBMR helps its clients to grow in these uncertain markets.

Prominent Players Operating In The Market Include:-Fortress Biotech, Teva Pharmaceutical Industries Ltd, Amerigen Pharmaceuticals Limited, Mylan N.V., Bausch Health, H. Lundbeck A/S and others.

The Menkes Syndrome market accounted to USD 17.26 Billion in 2016 growing at a CAGR of 8.1% during the forecast period of 2019 to 2024.

Market Definition: Menkes Syndrome Market-Menkes syndrome is also known as steely hair disease is a rare, X-linked genetic disorder of copper metabolism caused by gene mutations of copper transporter ATP7A.Because of the mutation in copper transport gene, copper is unavailable to reach to the various cells where it is essential for the structure and function of various enzymes. It is characterized by sparse, kinky hair, failure to thrive and progressive deterioration of the nervous system.

According to the statistics published by National Organization for Rare Disorders, Inc, an estimated population of Menkes syndrome is about 1 in 100,000-250,000 live birth. Presence of refined healthcare infrastructure and emerging new market are the key factors for growth of this market.

Market Drivers

Market Restraints

Browse Full Report with Details TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-menkes-syndrome-market

ThisMenkes Syndrome Marketreport provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

Browse 60 Market Data Tables and 220 Figures spread through 320 Pages and in-depth TOC on Menkes Syndrome Market .

Menkes Syndrome Marketis highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Menkes Syndrome Market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

For More Information or Query or Customization Before Buying, Visit @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-menkes-syndrome-market

Global Menkes Syndrome Market Segmented ByType (Neurodegenerative Disease, X-linked Copper Malabsorption)

Global Menkes Syndrome Market Segmented byDistribution Channel (Hospital Pharmacies, Retail Pharmacies)

Global Menkes Syndrome Market SegmentedBy Therapy Type (Gene Therapy, Copper Injection Therapy), Drugs (Penicillamine, Droxidopa and Others),

Global Menkes Syndrome Market Segmented ByRoute of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics and Others)

Some Of The Major Players Operating In The Menkes Syndrome Market AreFortress Biotech, Teva Pharmaceutical Industries Ltd, Amerigen Pharmaceuticals Limited, Mylan N.V., Bausch Health, H. Lundbeck A/S and others.

Key Questions Answered in Menkes Syndrome Market Report:-

What Our Report Offers:

The Menkes Syndrome report has been produced with the systematic gathering and analysis of information about individuals or organizations conducted through social and opinion research. With the studies, insights and analysis mentioned in the report, you get comprehensible idea about the marketplace with which you can take business decisions quickly and easily. The worldwide Menkes Syndrome advertise report comprises of all the organization profiles of the key players and brands. Market definition covered in this Menkes Syndrome report studies the market drivers and market restraints with which businesses can get idea of whether to increase or decrease the production of a particular product.

Detailed TOC of Menkes Syndrome Market Research Report: Table of Contents

1 Introduction

2Market Segmentation

3 Market Overview

4 Executive Summaries

5 Premium Insights

6 Regulatory Procedure

7 Menkes Syndrome Market, By Type

8 Menkes Syndrome Market, by disease type

9 Menkes Syndrome Market, By Deployment

10 Menkes Syndrome Market, By End User

11 Menkes Syndrome Market, By Distribution Channel

12 Menkes Syndrome Market, By Geography

13 Menkes Syndrome Market, Company Landscape

14 Company Profile

Continued!!!

To Gain More Insights into the Market with Detailed Table of Content and Figures, Click here-https://www.databridgemarketresearch.com/toc/?dbmr=global-menkes-syndrome-market

We can also customize this report and provide individual chapters or a region-wise breakdown report such as North America, Europe or Asia. Also, if you have any special requirements, ([emailprotected]) please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 819+2 7475

Email:[emailprotected]+

Originally posted here:
Menkes SyndromeIndustry 2020 With Covid-19 Impact on Market Research by Size, Top Leading Countries, Companies, Consumption, Drivers, Trends, Forces…

Wexner Medical Center performs gene therapy brain infusion for Parkinson’s disease – The Highland County Press

For the first time ever, a team of neurologists and neurosurgeons atThe Ohio State University Wexner Medical CenterandThe Ohio State College of Medicinehas performed a novel gene therapy brain infusion to treat a patient with Parkinsons disease.

This multicenter, Phase 1bclinical safety studyis sponsored byBrain Neurotherapy Bio, Inc.and funded by theCalifornia Institute for Regenerative Medicineto test GDNF gene therapy in patients with early to moderate stages of Parkinsons disease. The one-time treatment involves infusion of a gene therapy solution into deep structures of the brain that are affected by the disease.

Parkinsons disease is a neurodegenerative movement disorder that affects one million people in the United States. Degeneration of neural pathways deep in the brain causes symptoms such as tremor, slow movement and behavioral abnormalities, said Ohio State neurosurgeon Dr. James Brad Elder who performed the gene therapy surgery on Aug. 25.

The overall goal of this gene therapy treatment strategy is to slow the neurologic deterioration associated with Parkinsons disease by enhancing levels of a naturally occurring growth factor called GDNF. Targeting gene therapy delivery to the putamen, a deep brain structure affected by Parkinsons disease, will hopefully improve overall quality of life, Elder said.

The patient, a 55-year-old Ohio man first diagnosed with Parkinsons disease in 2008, takes medicine to help control his progressively worsening disease. He said the gene therapy surgery gives him hope that his disease wont get any worse, and that he may even feel better without medications. But he added that it could take up to six months before he notices any improvements.

There has long been evidence in animal and cell culture models of Parkinson’s disease suggesting that glia cell derived neurotrophic factor (GDNF) has promise as a therapy for the disease, said Dr. Sandra Kostyk, director of theMovement Disorders Divisionat Ohio State Wexner Medical Center. Patients with Parkinsons disease and related disorders are diagnosed and treated in the Movement Disorders clinics and neurosurgery programs at Ohio State.

One of the biggest clinical hurdles has been getting the molecule to the regions in the brain that would benefit these patients the most. GDNF is a relatively large molecule that cant be administered as a pill, nor intravenously, since it cant penetrate the blood brain barrier.

This new targeted gene delivery approach overcomes many of the obstacles that have slowed GDNF clinical trial research and is expected to facilitate the production of a continuous supply of GDNF to a critical region of the brain affected by Parkinsons disease.

This is a onetime treatment strategy that could have ongoing lifelong benefits. Though its hoped that this treatment will slow disease progression, we dont expect this strategy to completely stop or cure all aspects of the disease.Were cautiously optimistic as this research effort moves forward, Kostyk said.

Brain Neurotherapy Bio is a biotechnology startup company founded in 2018 byDr. Krystof Bankiewiczto develop gene therapies for neurological disorders. Bankiewicz is also a member of Ohio State Wexner Medical CentersNeurological Institute.

Ive been investigating therapeutic gene therapy approaches for Parkinsons disease for nearly 30 years, and this marks a significant milestone that may lead to major therapeutic opportunities for those suffering with this devastating condition, said Bankiewicz, who is CEO and chairman of the board of Brain Neurotherapy Bio.

Additional sites for this clinical trial include the University of California San Francisco and the University of California Irvine medical centers. For more information, emailOSUgenetherapyresearch@osumc.edu.

See the original post here:
Wexner Medical Center performs gene therapy brain infusion for Parkinson’s disease – The Highland County Press